Literature DB >> 14593522

Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Alessandra Gianviti1, Alberto E Tozzi, Laura De Petris, Alfredo Caprioli, Lucilla Ravà, Alberto Edefonti, Gianluigi Ardissino, Giovanni Montini, Graziella Zacchello, Alfonso Ferretti, Carmine Pecoraro, Tommaso De Palo, Angela Caringella, Maurizio Gaido, Rosanna Coppo, Francesco Perfumo, Nunzia Miglietti, Ilse Ratsche, Rosa Penza, Giovambattista Capasso, Silvio Maringhini, Salvatore Li Volti, Carmen Setzu, Marco Pennesi, Alberto Bettinelli, Leopoldo Peratoner, Ivana Pela, Elio Salvaggio, Giuliana Lama, Salvatore Maffei, Gianfranco Rizzoni.   

Abstract

Many factors have been proposed as predictors of poor renal prognosis in children with hemolytic uremic syndrome (HUS), but their role is still controversial. Our aim was to detect the most reliable early predictors of poor renal prognosis to promptly identify children at major risk of bad outcome who could eventually benefit from early specific treatments, such as plasmapheresis. Prognostic factors identifiable at onset of HUS were evaluated by survival analysis and a proportional hazard model. These included age at onset, prodromal diarrhea (D), leukocyte count, central nervous system (CNS) involvement, and evidence of Shiga toxin-producing Escherichia coli (STEC) infection. Three hundred and eighty-seven HUS cases were reported; 276 were investigated for STEC infection and 189 (68%) proved positive. Age at onset, leukocyte count, and CNS involvement were not associated with the time to recovery. Absence of prodromal D and lack of evidence of STEC infection were independently associated with a poor renal prognosis; only 34% of patients D(-)STEC(- )recovered normal renal function compared with 65%-76% of D(+)STEC(+), D(+)STEC(-) and D(-)STEC(+ )patients. In conclusion, absence of both D and evidence of STEC infection are needed to identify patients with HUS and worst prognosis, while D(-) but STEC(+) patients have a significantly better prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593522     DOI: 10.1007/s00467-003-1262-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  41 in total

1.  Detection of serum antibodies to the lipopolysaccharide of Escherichia coli O103 in patients with hemolytic-uremic syndrome.

Authors:  I Luzzi; A E Tozzi; G Rizzoni; A Niccolini; I Benedetti; F Minelli; A Caprioli
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

2.  Genetic studies into inherited and sporadic hemolytic uremic syndrome.

Authors:  P Warwicker; T H Goodship; R L Donne; Y Pirson; A Nicholls; R M Ward; P Turnpenny; J A Goodship
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.

Authors:  N Banatvala; P M Griffin; K D Greene; T J Barrett; W F Bibb; J H Green; J G Wells
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique.

Authors:  B Decludt; P Bouvet; P Mariani-Kurkdjian; F Grimont; P A Grimont; B Hubert; C Loirat
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

6.  Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.

Authors:  Wayne L Chandler; Srdjan Jelacic; Daniel R Boster; Marcia A Ciol; Glyn D Williams; Sandra L Watkins; Takashi Igarashi; Phillip I Tarr
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

7.  Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group.

Authors:  A Caprioli; I Luzzi; F Rosmini; P Pasquini; R Cirrincione; A Gianviti; M C Matteucci; G Rizzoni
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

8.  Changes in the postenteropathic form of the hemolytic uremic syndrome in children.

Authors:  N A Coad; T Marshall; B Rowe; C M Taylor
Journal:  Clin Nephrol       Date:  1991-01       Impact factor: 0.975

9.  Haemolytic-uraemic syndrome: an analysis of prognostic features.

Authors:  R S Trompeter; R Schwartz; C Chantler; M J Dillon; G B Haycock; R Kay; T M Barratt
Journal:  Arch Dis Child       Date:  1983-02       Impact factor: 3.791

10.  Haemolytic uraemic syndrome: prognostic factors in children over 3 years of age.

Authors:  C Renaud; P Niaudet; M F Gagnadoux; M Broyer; R Habib
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

View more
  14 in total

1.  Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome.

Authors:  Gianluigi Ardissino; Valeria Daccò; Sara Testa; Cristina Felice Civitillo; Francesca Tel; Ilaria Possenti; Mirco Belingheri; Pierangela Castorina; Nicolò Bolsa-Ghiringhelli; Silvana Tedeschi; Fabio Paglialonga; Stefania Salardi; Dario Consonni; Elena Zoia; Patrizia Salice; Giovanna Chidini
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

2.  Characteristics of children with sporadic hemolytic uremic syndrome in a single Northern California center.

Authors:  Gia Oh; Keith K Lau
Journal:  Int Urol Nephrol       Date:  2011-11-25       Impact factor: 2.370

3.  Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

4.  Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome.

Authors:  Maurizio Brigotti; Alfredo Caprioli; Alberto E Tozzi; Pier Luigi Tazzari; Francesca Ricci; Roberto Conte; Domenica Carnicelli; Maria Antonietta Procaccino; Fabio Minelli; Alfonso V S Ferretti; Fabio Paglialonga; Alberto Edefonti; Gianfranco Rizzoni
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement.

Authors:  Frank Donnerstag; Xiaoqi Ding; Lars Pape; Eva Bültmann; Thomas Lücke; Jan Zajaczek; Ludwig Hoy; Anibh Martin Das; Heinrich Lanfermann; Jochen Ehrich; Hans Hartmann
Journal:  Eur Radiol       Date:  2011-10-08       Impact factor: 5.315

6.  Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China.

Authors:  Shui-Ai Zhao; Bo-Tao Ning; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2017-03-28       Impact factor: 2.764

Review 7.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

8.  CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings.

Authors:  Marc Steinborn; Steffen Leiz; Klaus Rüdisser; Martin Griebel; Thomas Harder; Helmut Hahn
Journal:  Pediatr Radiol       Date:  2004-07-29

Review 9.  Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.

Authors:  Lindsay S Keir; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2013-07-11       Impact factor: 3.714

Review 10.  Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.

Authors:  Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.